55 Corporate Drive
89 articles with Sanofi
Recipharm and Sanofi have completed the acquisition of Sanofi’s inhalation contract manufacturing business including a manufacturing facility located in Holmes Chapel, UK.
FDA Approves Libtayo® (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Libtayo is the third anti-PD-1 approved in the U.S.
Novo Nordisk is laying off 400 staffers so it can shift funds toward biological and technological innovation.
Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults ADDING MULTIMEDIA
Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved AJOVYTM (fremanezumab-vfrm) injection for the preventive treatment of migraine in adults.
Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis
Results on skin clearing, itch and certain quality of life measurements were presented today as a late-breaking oral presentation at the 27th EADV Congress
FDA to Review Supplemental Biologics License Application for Praluent® (alirocumab)Injection as Potential Treatment to Reduce Major Adverse Cardiovascular Events
Last month, FDA also approved Praluent label update for some patients currently requiring LDL apheresis therapy
FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy
As Brexit creeps closer and closer, the British government, as well as pharmaceutical companies and the European Medicines Agency, are preparing contingency plans for dealing with the possibility that healthcare-related companies will not have contracts in place in time.
Vantage Pharma published a report that reviewed the biopharma and medical technology trends for the year-to-date. Broadly speaking, for biotech companies, venture capital investment is up and mergers and acquisitions is down, while for the medical device company it’s the reverse.